INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms
Q4 2024 Management View CEO Raymond Tesi highlighted the transformative potential of 2024 for INmune Bio, emphasizing upcoming milestones. He noted the Phase 2 trial of XPro for Alzheimer's disease, ...
The Nassau Guardian17h
Splice N Connect CARIFTA Trials set for April 4-6
Under the theme ‘We name Bahamas’, the Bahamas Association of Athletic Associations’ (BAAA) is set to stage what is ...